Machine learning algorithm effectively identifies individuals with probable familial hypercholesterolemia

NewsGuard 100/100 Score

The FH Foundation, a leading research and advocacy organization, announced today that a machine learning algorithm effectively identified individuals with probable familial hypercholesterolemia (FH) for the first time at a national scale through its FIND FH initiative. FH is a common genetic disorder that carries a 20-times higher risk for life-threatening cardiovascular disease, but today less than 10 percent of the 1.3 million Americans born with FH are diagnosed.

The FH Foundation study, designed to validate and implement the FIND (Flag, Identify, Network, Deliver) FH model, was published online in The Lancet Digital Health and simultaneously presented at the 2019 FH Global Summit in Atlanta.

In "Precision screening for familial hypercholesterolemia: a machine learning study applied to electronic health encounter data," the authors highlight that the FIND FH model successfully scanned large, diverse, and disparate healthcare encounter databases to flag individuals with probable FH. The FIND FH model performed comparably with high precision across two distinct types of healthcare data: a national healthcare encounter database and the Oregon Health & Science University (OHSU) electronic health records (EHR) database. Eight out of 10 times the model correctly identified FH individuals, significantly reducing the number of people needed to be screened.

Precision screening for FH is now a reality in any healthcare system with electronic health records. We no longer need to screen everyone to find individuals who are at genetic risk for heart attacks and strokes. After further clinical evaluation, if an FH diagnosis is made, it will trigger screening of relatives as well. While FH is manageable, the greatest benefit is from treatment earlier in life."

Daniel J. Rader, MD, chair of the department of Genetics in the Perelman School of Medicine at the University of Pennsylvania, chief scientific advisor of the FH Foundation and study co-author

Today, population-based screening for FH in the U.S. has not been widely implemented, leaving families at continued risk, even though the American Heart Association, American College of Cardiology, Centers for Disease Control and Prevention and the World Health Organization recommend screening to identify families with FH. Precision screening allows a healthcare system or provider to focus on screening those individuals most at risk and more likely to benefit from early diagnosis and intervention.

"People born with familial hypercholesterolemia develop cardiovascular damage by puberty, often culminating in early heart attacks or the need for surgery as young or middle-aged adults," said Katherine Wilemon, founder and CEO of the FH Foundation and study co-author. "Since diagnosis of this deadly but treatable condition has stalled in the American medical system, the FH Foundation harnessed artificial intelligence and big data to accelerate identification of those most likely to have FH."

Specific study results showed the FIND FH screening algorithm correctly identified individuals with probable FH 87 percent of the time in the national database and 77 percent of the time in the Oregon Health & Science University EHR. By using clinical data such as medication use and medical history, the FIND FH model identified individuals who would be overlooked by relying just on LDL-cholesterol cut-offs (traditionally greater than 190 mg/dL) - often used for identifying people with the condition.

"The FIND FH model carries the promise of efficiently identifying many of the over 1 million undiagnosed individuals with FH in the U.S.," said Kelly Myers, the FH Foundation chief technology officer and study co-author. "The FIND FH model performed equally well on data from integrated healthcare systems as well as a large national healthcare encounter database, suggesting that it will be applicable to implementation at a variety of healthcare institutions and organizations."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals breakthrough in non-invasive detection of endometrial cancer